Shots:
- The US FDA has granted clearance to the Onclarity HPV Self-Collection Kit & approved the BD Onclarity HPV Assay for at-home use, expanding access to cervical cancer screening
- The kit is tested with the BD Onclarity HPV Assay, detecting all high-risk HPV genotypes with individual & pooled results, & processed on the automated BD COR System. Also, NCI partnered with Waters via the SHIP trial to evaluate self-collection accuracy for HPV testing
- Waters is building partnerships to enable nationwide access, with prescription-based kits expected to be covered by insurance & designed to improve early detection and reduce cervical cancer risk
Ref: PRnewswire | Image: Waters | Press Release
Related News: Becton Dickinson’s Biosciences & Diagnostic Solutions Business to Combine with Waters in a $17.5B Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
